Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven Grwth 3 Regulatory News (MIG3)

Share Price Information for Maven Grwth 3 (MIG3)

Share Price is delayed by 15 minutes
Get Live Data
43.80    0.00 (0.00%)
Bid:
42.80
Ask:
44.80
Spread: 2.00 (4.673%)
Market Cap: £68.37m
MIG3 Live PriceLast checked at - London Stock Exchange

Intraday Maven Grwth 3 Share Chart

Dividend Declaration

6 Feb 2024 11:07

RNS Number : 1954C
Maven Income and Growth VCT 3 PLC
06 February 2024
 

 

Maven Income and Growth VCT 3 PLC

 

Proposed Final Dividend

 

On 18 December 2023, the Directors of Maven Income and Growth VCT 3 PLC ("the Company") announced that the unaudited net asset value of the Company as at 30 November 2023 was 52.48p per Ordinary Share.

 

The Directors propose that a final dividend of 2.15p per Ordinary Share, in respect of the year ended 30 November 2023, be paid on 3 May 2024 to Shareholders on the register at close of business on 22 March 2024.

 

As Shareholders will be aware from recent Annual and Interim Reports, decisions on distributions take into consideration a number of factors, including the availability of surplus revenue, the realisation of capital gains, the adequacy of distributable reserves and the VCT qualifying level. The Board and the Manager recognise the importance of tax-free distributions to Shareholders and, subject to the conditions set out above, will seek, as a guide, to pay an annual dividend that represents 5% of the NAV per share at the immediately preceding year end. This final dividend will bring total distributions for the financial year to 2.65p per Ordinary Share, representing an annual yield of 4.62%.

 

Since the Company's launch, and after receipt of this final dividend, a total of 99.72p per share will have been distributed in tax-free dividends. It should be noted that the effect of paying dividends is to reduce the NAV of the Company by the total cost of the distribution.

 

 

Dividend Investment Scheme

The Company has in place a Dividend Investment Scheme (DIS) through which Shareholders may elect to have their dividend payments used to apply for new Ordinary Shares issued by the Company under the standing authority requested from Shareholders at Annual General Meetings. Shares issued under the DIS should qualify for VCT tax reliefs applicable for the tax year in which they are allotted, subject to an individual Shareholder's particular circumstances. Terms & conditions of the scheme, together with a mandate form, are available from the Company's webpage at: mavencp.com/migvct3.

Shareholders who have not previously applied to participate in the DIS and who wish to do so in respect of the dividend payable on 3 May 2024, should ensure that a mandate form is received by the Company's Registrar, The City Partnership (UK) Limited, prior to the dividend election date of 12 April 2024. Election to participate in the DIS can also be made through the Registrar's online investor hub at: maven-cp.cityhub.uk.com.

 

Further to the information disclosed above, the Directors confirm that they are satisfied that all inside information (as defined by Article 7 of the Market Abuse Regulation (596/2014/EU)) that the Directors and the Company may have in their possession relating to the Company during the 30 day closed period leading up to the announcement of its annual results for the year ended 30 November 2023 has been or will be notified to a regulatory information service.

 

Issued on behalf of the Board

Maven Capital Partners UK LLP

Company Secretary

6 February 2024

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DIVEAFAKEELLEFA
Date   Source Headline
27th Mar 20251:06 pmRNSIssue of Equity
27th Mar 202510:25 amRNSUpdate re: Offers for Subscription
24th Mar 20253:53 pmRNSUnaudited Net Asset Value
18th Mar 20253:37 pmRNSAnnual Financial Report
28th Feb 20254:32 pmRNSTransaction in Own Shares
27th Feb 20251:54 pmRNSUnaudited NAV and Proposed Final Dividend
19th Feb 202510:17 amRNSDirector/PDMR Shareholding
19th Feb 202510:14 amRNSDirector/PDMR Shareholding
19th Feb 202510:06 amRNSIssue of Equity
28th Jan 202512:15 pmRNSStatement re Offer for Subscription
18th Dec 20249:35 amRNSIssue of Equity
13th Dec 20242:42 pmRNSNet Asset Value(s)
14th Nov 20242:55 pmRNSResult of General Meeting
25th Oct 20243:49 pmRNSTransaction in Own Shares
27th Sep 20244:31 pmRNSPublication of a Prospectus
6th Sep 202410:25 amRNSDirector/PDMR Shareholding
6th Sep 202410:01 amRNSIssue of Equity
5th Sep 20242:26 pmRNSStatement re Dividend Investment Scheme
5th Sep 20241:40 pmRNSUnaudited Net Asset Value
18th Jul 20245:27 pmRNSHalf-year Report
10th Jul 20245:08 pmRNSTransaction in Own Shares
8th Jul 20244:07 pmRNSStatement re NAV and Interim Dividend
18th Jun 202411:53 amRNSStatement re Intended Offers for Subscription
10th May 20244:11 pmRNSTransaction in Own Shares
3rd May 20249:35 amRNSDirector/PDMR Shareholding
3rd May 20249:33 amRNSIssue of Equity
2nd May 20241:31 pmRNSResult of AGM
1st May 202410:06 amRNSDirector/PDMR Shareholding
1st May 202410:03 amRNSIssue of Equity
26th Apr 20242:40 pmRNSNet Asset Value - Dividend Investment Scheme
19th Apr 202412:17 pmRNSIssue of Supplementary Prospectus
5th Apr 20243:37 pmRNSIssue of Equity
28th Mar 202410:16 amRNSStatement re Offer for Subscription
27th Mar 202410:36 amRNSIssue of Equity
22nd Mar 202410:14 amRNSIssue of Supplementary Prospectus
20th Mar 20243:46 pmRNSUnaudited Net Asset Value
15th Mar 20245:18 pmRNSAnnual Financial Report
21st Feb 20244:24 pmRNSTransaction in Own Shares
8th Feb 202410:30 amRNSDirector/PDMR Shareholding
8th Feb 202410:28 amRNSDirector/PDMR Shareholding
8th Feb 202410:15 amRNSIssue of Equity
6th Feb 202411:07 amRNSDividend Declaration
19th Dec 20233:25 pmRNSIssue of Equity
18th Dec 20235:17 pmRNSUnaudited Net Asset Value
5th Dec 202311:42 amRNSDirectorate Change
9th Nov 20233:47 pmRNSResult of General Meeting
8th Nov 20234:01 pmRNSTransaction in Own Shares
7th Nov 20234:47 pmRNSTransaction in Own Shares
19th Oct 20234:15 pmRNSNet Asset Value
13th Oct 20234:56 pmRNSPublication of a Prospectus

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.